Analysts See Upside Potential for DCOR ETF and Holdings

Market analysts project significant upside for the Dimensional US Core Equity 1 ETF (DCOR) at 14.23%. Crexendo Inc (CXDO), Personalis Inc (PSNL), and Oramed Pharmaceuticals Inc (ORMP) are highlighted as promising holdings, with upsides exceeding 36%. Investors are urged to research further.

Date: 10-01-2025

AI Rating: 7

Earnings Potential of DCOR and Its Holdings
According to the report, the implied analyst target price for the Dimensional US Core Equity 1 ETF (DCOR) is $73.78 per unit, while its recent trading price is $64.59. This difference indicates a potential upside of 14.23%. Such upside suggests positive sentiment among analysts toward the ETF's overall future performance.

Individual Holdings Insights
Three significant underlying holdings within the DCOR include Crexendo Inc (CXDO), Personalis Inc (PSNL), and Oramed Pharmaceuticals Inc (ORMP).

- CXDO's recent price is $5.38, with a notable upside of 40.95% to its average target price of $7.58/share.
- PSNL is currently trading at $5.60, with analysts projecting a 36.61% upside to the target price of $7.65/share.
- ORMP has a recent price of $2.38, with expectations of a 36.55% increase to a target of $3.25/share.

Each of these stocks is showing substantial expected upside, which could significantly affect their market performance and investor interest.

Investor's Caution
While these analyst targets reflect optimism about the stocks' performances, they also warrant caution. A high price target compared to current trading prices can indicate that analysts may be overly optimistic. Should future performance not align with these expectations, there may be a risk of target price downgrades. Therefore, it's crucial for investors to conduct further research on market conditions, company fundamentals, and industry dynamics surrounding these stocks to validate the analysts' optimism.

Stocks: DCOR CXDO PSNL ORMP